Not all networks are created equal, and the type of partners firms engage with can significantly impact the nature of the innovation that occurs. Studies show that the diversity of partners in a network is a critical factor in determining the success of innovation efforts.
For example, firms that collaborate with customers tend to focus on incremental innovations—improvements to existing products or processes that meet the specific needs of their clients. This type of innovation is relatively low risk and ensures that the firm’s innovations are closely aligned with market demand. On the other hand, firms that engage with suppliers, universities, and consultants are more likely to develop radical innovations that introduce entirely new products or services to the market. These innovations tend to be more disruptive and carry higher risks but offer the potential for greater rewards.
Engagement with universities and research institutions is particularly important for firms seeking to pursue radical innovations. These partnerships allow firms to tap into cutting-edge research and emerging technologies, providing them with a competitive advantage in developing new products and services. In contrast, firms that rely solely on internal resources or customer feedback are more likely to focus on incremental improvements.
The value of diversity in partners is also evident in the biotechnology sector, where firms collaborate with a wide range of partners, including universities, research institutions, and other biotech companies, to bring new products to market. These collaborations enable firms to combine their specialized knowledge with the expertise of others, accelerating the pace of innovation and reducing the time it takes to bring new drugs and therapies to patients.